All In Biotech

Drug Trial Radar · NCT00038662

Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

Last checked: Nov 20, 2026Latest source record: Aug 15, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

May 2002

Primary completion

Not stated

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Jun 4, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).

Conditions

  • Prostatic Neoplasms

Interventions

  • AtrasentanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama

    Homewood, Alabama

  • Alaska Clinical Research Center, LLC

    Anchorage, Alaska

  • Arkansas Urologial Associates, PA

    Little Rock, Arkansas

  • San Diego Urology Center

    La Mesa, California

  • Western Clinical Research Inc

    Torrance, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Southeastern Urological Center, PA

    Tallahassee, Florida

  • Northwestern University

    Chicago, Illinois

  • Johns Hopkins Oncology Center

    Baltimore, Maryland

  • Sheldon Freedman MD

    Las Vegas, Nevada

  • VA Medical Center(111)

    Reno, Nevada

  • Nevada Urology Associates

    Reno, Nevada

  • Carolinas Medical Centre

    Charlotte, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Urologic Specialists Of Oklahoma, Inc.

    Tulsa, Oklahoma

  • Oregon Urology Specialists

    Eugene, Oregon

  • Urological Assoc. of Lancaster

    Lancaster, Pennsylvania

  • University Of Pittsburgh

    Pittsburgh, Pennsylvania

  • Center for Urologic Care

    West Reading, Pennsylvania

  • Ntouch Research Corporation

    Dallas, Texas

  • Salt Lake Research

    Salt Lake City, Utah

  • Jeffrey Frankel, M.D.

    Seattle, Washington

  • University of Washington Medical Center

    Seattle, Washington

  • Tom Baker Cancer Center

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Cal Andreou, MD

    Surrey, British Columbia, Canada

  • Can-Med Medical Research Inc

    Victoria, British Columbia, Canada

  • Bruce W. Palmer Urology Inc.

    Kentville, Nova Scotia, Canada

  • The Male Health Centres

    Barrie, Ontario, Canada

  • Burlington Professional Centre

    Burlington, Ontario, Canada

  • Hamilton & District Urology Association

    Hamilton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Quest Clinical Trials

    Markham, Ontario, Canada

  • Guardian Medical Arts Bldg.

    North Bay, Ontario, Canada

  • Jack Barkin, MD

    North York, Ontario, Canada

  • The Male Health Centres

    Oakville, Ontario, Canada

  • Sunnybrook &Women's College Health Sciens Center

    Toronto, Ontario, Canada

  • Hopital Notre-Dame

    Montreal, Quebec, Canada

  • Chuq Pavillon Hotel-Dieu

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.